Malignant neoplasms of prostate (Q38926): Difference between revisions

From determinar.ia.br - Determine suas informações
Changed label, description and/or aliases in pt-br, en
Changed an Item
Property / Canonical URI
 
Property / Canonical URI: https://id.who.int/icd/entity/1552457716 / rank
 
Normal rank

Revision as of 04:11, 13 August 2026

Prostate cancer contributes significantly to the overall cancer burden and is the most common malignant neoplasm in men. The number of cases has steadily increased over recent decades, partly due to rising life expectancy. Additional contributing factors include aspects of the Western lifestyle, such as high-calorie diets and reduced physical activity. Epidemiological data suggest that incidence rates vary among populations, with the highest rates observed in individuals of African descent, followed by those of European descent, while rates are lowest in some Asian populations. The impact of prostate-specific antigen (PSA) screening on mortality reduction is currently under evaluation. Histopathological diagnosis and grading remain critical components in the clinical management of prostate cancer.
Language Label Description Also known as
default for all languages
2C82
    English
    Malignant neoplasms of prostate
    Prostate cancer contributes significantly to the overall cancer burden and is the most common malignant neoplasm in men. The number of cases has steadily increased over recent decades, partly due to rising life expectancy. Additional contributing factors include aspects of the Western lifestyle, such as high-calorie diets and reduced physical activity. Epidemiological data suggest that incidence rates vary among populations, with the highest rates observed in individuals of African descent, followed by those of European descent, while rates are lowest in some Asian populations. The impact of prostate-specific antigen (PSA) screening on mortality reduction is currently under evaluation. Histopathological diagnosis and grading remain critical components in the clinical management of prostate cancer.

      Statements